Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > 24-hour CEO
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(99)
•••
Comment by Aarcoron Dec 14, 2020 6:40pm
159 Views
Post# 32105413

RE:RE:RE:RE:RE:RE:24-hour CEO

RE:RE:RE:RE:RE:RE:24-hour CEOI won't ever advocate placing the future of the company on management successfully completing material deals (i.e. not the open-ended research type deals that have been all prior except hopefully Chiesi).  The company has to push forward by whatever means to advance xb3-001 to phase1 and as far as we all knew that was the plan until the other day.  So now we wait for someone to knock on the door and say we'd like to help you with 001 which, by the way, has not happened in 10 years.  Management has simply not been able to generate interest.  This stock would be several multiples its current value just clearing phase 1.  At that point, there would be more options for initiating phase 2.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities